# Cogent Biosciences

Source: https://onco.cc/companies/cogent-biosciences/  
OnCo record `cogent-biosciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cogent Biosciences makes bezuclastinib, a pill that blocks a mutated protein called KIT. It is being tested in a rare gut tumour called GIST and in systemic mastocytosis, a disease of overactive immune cells.

## Summary

Cogent Biosciences is a Waltham, Massachusetts and Boulder, Colorado company developing precision therapies for genetically defined diseases. Its lead candidate, bezuclastinib, is a selective tyrosine kinase inhibitor of KIT D816V and other KIT mutations. In November 2025 it reported positive top-line SUMMIT results in non-advanced systemic mastocytosis (FDA Breakthrough Therapy designation; NDA planned for year-end 2025) and awaited the phase 3 PEAK trial of bezuclastinib plus sunitinib in second-line gastrointestinal stromal tumours (GIST) and the registration-directed APEX trial in advanced systemic mastocytosis. Preclinical programmes include a JAK2 V617F mutant-selective inhibitor, a pan-KRAS(ON/OFF) inhibitor, and selective ErbB2 (HER2), PI3K-alpha and FGFR2 inhibitors. Cogent (formerly Unum Therapeutics) trades on Nasdaq as COGT and reported about 430 million US dollars pro forma cash in November 2025.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Waltham, MA
- Type: biotech
- Website: https://www.cogentbio.com/
- Ticker: COGT

## Notes

- PEAK and APEX results (expected November and December 2025) were not verified.

## Sources

- Official website: https://www.cogentbio.com/
- Pipeline and publications: https://www.cogentbio.com/pipeline-publications/
- Q3 2025 results and business update (SEC exhibit): https://www.sec.gov/Archives/edgar/data/1622229/000119312525261797/cogt-ex99_1.htm
- December 2020 public offering 8-K (SEC): https://www.sec.gov/Archives/edgar/data/1622229/000119312520308501/d72504d8k.htm

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [FGFR2](https://onco.cc/targets/fgfr2/), [HER2](https://onco.cc/targets/her2/), [KIT](https://onco.cc/targets/kit/), [KRAS](https://onco.cc/targets/kras/), [PIK3CA / PI3K-alpha](https://onco.cc/targets/pik3ca/)
- drugs: [Bezuclastinib](https://onco.cc/drugs/bezuclastinib/), [CGT4859](https://onco.cc/drugs/cgt4859/)
- trials: [(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis](https://onco.cc/trials/nct04996875/), [(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors](https://onco.cc/trials/nct05208047/), [(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis](https://onco.cc/trials/nct05186753/), [A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors](https://onco.cc/trials/nct06777316/)

---
JSON: https://onco.cc/api/v1/entities/cogent-biosciences.json